Radiation plus immunotherapy may make inoperable liver cancer operable
NCT ID NCT07305428
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study is testing whether combining stereotactic body radiation therapy (SBRT) with immunotherapy can shrink liver tumors that are too large or widespread to be surgically removed. The goal is to make these tumors operable, giving patients a chance at curative surgery. The study will enroll 30 adults with unresectable hepatocellular carcinoma (HCC) and will measure how many patients are successfully downstaged to become surgical candidates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stereotactic body radiation therapy (SBRT) followed by immunotherapy drugs
What this could lead to
If successful, this approach could allow some patients with inoperable liver cancer to become candidates for surgery, potentially improving their long-term survival.
What could go wrong
This is a very early pilot study with only 30 participants. It is not yet known if the combination will be effective or safe, and immunotherapy can cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Queen Mary Hospital
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact